Drugmakers Call for More Details in FDA Guidance on Assessing Pressor Effects

FDA draft guidance on assessing a new drug’s impact on blood pressure does not adequately explain the agency’s thinking on the use of smaller clinical trials and should incorporate a more risk-based approach, according to comments from three leading drug sponsors.
Source: Drug Industry Daily